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individual-level utilization, and costs between antihypertensive med-
ication users versus nonusers in adults with diabetes and con-
comitant hypertension. Methods: This longitudinal retrospective
observational research used Medical Expenditure Panel Survey house-
hold component pooled years 2006 to 2009 to analyze adults 18 years
or older with nongestational diabetes and coexistent essential hyper-
tension. Two groups were created: 1) antihypertensive medication
users and 2) no antihypertensive pharmacotherapy. We examined
average annualized health care costs and emergency department and
hospital utilization. Accounting for Medical Expenditure Panel Sur-
vey’s complex survey design, all analyses used longitudinal weights.
Logistic regressions examined the likelihood of utilization and
anytihypertensive medication use, and log-transformed multiple
linear regression models assessed costs and antihypertensive
medication use. Results: Of the 3261 adults identiﬁed with diabetes,
66% (n ¼ 2137) had concomitant hypertension representing
38.7 million individuals during 2006 to 2009. Signiﬁcantly, the 16%
(n ¼ 338) no antihypertensive pharmacotherapy group showed greatersee front matter Copyright & 2014, International S
r Inc.
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1.mean nights hospitalized (3.6 vs. 1.7, P ¼ 0.0120), greater all-cause
hospitalization events per 1000 patient months (41 vs. 24, P ¼ 0.0.007),
and lower mean diabetes-related and hypertension-related ambula-
tory visits. After adjusting for confounders, non-antihyper-
tensive medication users showed 1.64 odds of hospitalization, 29%
lower total, and 27% lower average annualized medical expenses
compared with antihypertensive medication users. Conclusions: In
adults with diabetes and coexistent hypertension, we observed
signiﬁcantly greater hospitalizations and lower costs for the non
antihypertensive pharmacotherapy group versus those using antihy-
pertensive medications. The short-term time horizon greater hospi-
talizations with lower expenses among non-antihypertensive
medication users with diabetes and concomitant hypertension war-
rant further study.
Keywords: antihypertensive medication, blood pressure, costs,
diabetes, hypertension, utilization.
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Diabetes affects an estimated 25.8 million individuals approxi-
mating 8.3% of the 2010 resident US population, while another 7
million presumably have undiagnosed diabetes [1]. Risks associ-
ated with developing diabetes, prediabetes, and/or insulin resist-
ance continue to rise [2]. Hypertension prevalence remains high
among adults with diabetes despite several years’ evidence for
better outcomes from tight blood pressure (BP) control [3,4]. A
reported 70% to 80% of those with type 2 diabetes have hyper-
tension [5,6]. During the years 2005 to 2008, 67% of the adults with
diabetes had BPs exceeding the accepted range for upper level
normal [7].
Although discussion continues about optimal target BP levels
[8–10], current guidelines recommend tight BP control for indi-
viduals with diabetes and concomitant hypertension [11–14]. Yet,several studies report suboptimal BP control [15–17], with only
38% of men and 25% of women with diabetes reaching target BP
levels [18]. Poor BP control increases risks for cardiovascular
events and microvascular complications [19–23], whereas low-
ering BP shows cardioprotective effects [24–27] and reduces eye
complications [28]. Moreover, the cohort with type 2 diabetes,
comorbid hypertension, and obesity in the US Study to Help
Improve Early evaluation and management of risk factors Lead-
ing to Diabetes reports signiﬁcantly greater physician ofﬁce visits
and emergency department (ED) utilization despite 92% of the
study respondents reporting having received antihypertensive
medications [29].
Despite aggressive BP control guidelines and continued poor
target BP levels in individuals with diabetes and coexistent
hypertension, few studies assess differences between antihyper-
tensive medication users and nonusers in individuals withociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 1 – 6 152diabetes and comorbid hypertension. In addition to diet and
lifestyle, prescription medication remains central in hyperten-
sion management [30,31]. Few studies examine differences in
health services utilization and costs in adults with diabetes and
concomitant hypertension between those using BP-controlling
medications and those not using antihypertensive pharmaco-
therapy. We lack important information about non-anti-
hypertensive medication users in adults with diabetes and coex-
istent hypertension.
This study sought to address this gap by, ﬁrst, quantifying
population-level information about individuals with diabetes and
coexistent hypertension and summarizing the differences
between those prescribed antihypertensive medications and
those reporting no antihypertensive medication use, and, second,
to determine the likelihood for ED utilization and hospitalization
and quantify the associated total and annual health care
expenses between the two groups.Methods
We conducted a retrospective observational longitudinal cross-
sectional study covering the years 2006 to 2009 among Medical
Expenditure Panel Survey household component (MEPS-HC) par-
ticipants aged 18 years and older diagnosed with diabetes and
concomitant hypertension. This research was approved by the
University of Maryland, Baltimore Institutional Review Board,
and classiﬁed as exempt from human subject research.
MEPS-HC is a subsample from the previous year’s National
Health Interview Survey sponsored by the National Center for
Health Statistics to collect household and individual-level infor-
mation about the civilian noninstitutionalized US population.
The MEPS sampling frame uses an overlapping panel design to
conduct interviews during ﬁve separate in-person rounds over 2
years to gain information about health care usage, expenditures,
insurance coverage, source of payment, access to care, and
quality. Inferences using weighted MEPS-HC data provide
national estimates representative of the civilian noninstitution-
alized US population [32].
We included panel 11 (2006–2007), panel 12 (2007–2008), and
panel 13 (2008–2009) from the MEPS public use longitudinal data
ﬁles. MEPS public use ﬁles were merged and complete panel
periods pooled while preserving sample weights. We restricted
our sample to those with diagnoses for diabetes and essential
hypertension identiﬁed by the MEPS medical conditions ﬁle
variable “CCCODEX” labeled clinical classiﬁcation code [33,34].
MEPS derived the CCCODEX variable by using the Clinical Clas-
siﬁcations Software (CCS) disease categorization scheme for
International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁca-
tion (ICD-9-CM) codes developed by the Healthcare Cost and
Utilization Project under the auspices of the Agency for Health-
Care Research and Quality. CCS collapsed ICD-9-CM’s multitude of
codes into fewer clinically meaningful categories. To identify
those with diabetes mellitus, we used the CCS codes “49,”
diabetes without complications, and “50,” diabetes with compli-
cations. For essential hypertension, we used the CCS code “98,”
which aggregated the ICD-9-CM diagnosis codes 401.1 and 401.9
into a single category [35]. We excluded subjects who became
ineligible to participate in the survey as designated by MEPS
longitudinal weights of 0 or less, as well as women with gesta-
tional diabetes, and individuals younger than 18 years of age.
Antidiabetic and antihypertensive medication use was iden-
tiﬁed by using MULTUM therapeutic class codes from the MEPS
prescribed medicines ﬁles. We then divided the cohort into two
groups: 1) subjects using antihypertensive medications and 2)
subjects not using antihypertensive medications.To derive health care expenses, we ﬁrst measured health
services utilization by averaging the total number for each
separate ofﬁce-based and outpatient event and each unique
prescription drug ﬁll as well as the number of ED visits and
hospitalization events per 1000 patient months during the 2-year
panel period. A total expense for each event measured total
health care expenses per individual by summing all health
services utilization and prescription drug expenses over the 2-
year period. Medical utilization expenses summed only health
services utilization expenses without prescription drug expenses.
Diabetes- and hypertension-related utilization and drug
expenses were identiﬁed from medical condition and event ﬁles.
Annualized average total, medical utilization, prescription drug,
and disease-speciﬁc expenses were calculated for analysis.
Covariates used for baseline descriptive analysis included
sociodemographic characteristics and clinically relevant factors.
We used the Deyo adaptation of the Charlson comorbidity index
(CCI) as a measure of risk adjustment and disease burden [36]. To
construct the CCI for this cohort, we restricted comorbidities to
secondary diagnosis not related to diabetes or hypertension [37].
Overall perceived health status was assessed by using the MEPS
health and well-being variable labeled “health in general” with an
MEPS-assigned variable name “ADGENH” derived from the SF-12
v2 survey. After reviewing this variable’s sample distribution, we
collapsed this variable’s categories for “excellent” and “very good”
into one level labeled “excellent-very good,” kept the category
“good” as is and used the label “good,” and collapsed the categories
signifying “fair” and “poor” into another labeled “fair-poor.”
MEPS public use ﬁles provided only three-digit ICD-9-CM codes
giving broad diagnostic categories. MEPS public use ﬁles used
either the three-digit “250” ICD-9-CM code for diabetes omitting
the ﬁve-digit subclassiﬁcations needed to classify individuals with
diabetes as type 1 or type 2 or the CCS codes described earlier. To
address this limitation, we included a variable for diabetes
medication use based on pharmacological treatment guidelines
outlined by the American Diabetes Association [38]. We assumed
that insulin approximated only type 1 diabetes; oral antidiabetic
(OAD) approximated only type 2 diabetes; insulin þ OAD indicated
diabetes disease severity; and no antiglycemic medication use
approximated those controlled by diet and exercise.
Antihypertensive medication use versus none was our primary
independent variable. The outcomes of interest were the like-
lihood of ED utilization and in-patient hospitalization, and annual-
ized average total health care and medical expenses per subject.
Descriptive and basic statistics described the population’s baseline
attributes and compared outcomes between antihypertensive
medication users versus none. Logistic regression models were
applied to assess the association between the likelihood for ED
utilization or hospitalization and antihypertensive medication use.
Because the cost data were skewed, linear regression models with
log transformation were used to assess the association between
annualized average total or medical expenses and antihyperten-
sive medication use [39]. Because other factors besides hyper-
tension or antihypertensive medication use may affect utilization,
such as well-being, we conducted additional subgroup analysis to
examine the differences in medical utilization among patients
with various perceived health statuses and comorbidity levels.
All data analyses applied longitudinal weights for estimates
accounting for the complex survey design and were performed by
using SAS 9.2 (SAS institute, Cary, NC). The level of statistical
signiﬁcance was set a priori at α ¼ 0.05 for all analyses.Results
As shown in Figure 1, from the total diabetes sample (n ¼ 3261),
approximately 66% (n ¼ 2137) had diabetes and coexistent
MEPS longitudinal data files (2006-2009, panels 11, 12, 13) (N = 47,260) 
Weighted frequency = 9,23,228,403 
Standard deviation of weighted frequency = 16,518,973 
Including subjects with longitudinal weight >0 (n = 46,887) 
Weighted frequency = 9,15,122,313 
Standard deviation of weighted frequency = 16,386,232 
Subjects (> 18 years) with nongestational diabetes (n = 3,261) 
Weighted frequency = 59,271,457 
Standard deviation of weighted frequency = 1,520,427 
Study population: subjects (> 18 years) with diabetes and hypertension (n = 2,137) 
Weighted frequency = 38,697,003 
Standard deviaon of weighted frequency = 1,167,296
Subjects (> 18  years) with diabetes and 
hypertension and using antihypertensive 
medications (n = 1,799) 
Weighted frequency = 32,697,480 
Standard deviation of weighted
frequency = 1,029,398
Subjects (> 18 years) with diabetes and 
hypertension and not using 
antihypertensive medications (n = 338) 
Weighted frequency = 5,999,523 
Standard deviation of weighted
frequency = 424,449
Fig. 1 – Patient selection. MEPS, Medical Expenditure Panel Survey.
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38.7 million (weighted SD 1.17 million). Of these, approximately
84% (n ¼ 1799) used one or more hypertension-controlling
medications (weighted population frequency 32.70 million;
weighted SD 1.02 million) and roughly 16% (n ¼ 338) reported
no hypertension-controlling pharmacotherapy (weighted popu-
lation frequency 6 million; weighted SD 0.42 million).
Table 1 presents results for the study cohort’s descriptive
characteristics (mean age 62.9 years; mean family total income
$50,820). The overall sample was predominately younger (age 18–
64 years, 55%), female (52%), of white racial identity (77%), from
the southern US geographical region (42%), high school educated
(50%), insured with private insurance (57%), from higher income
levels, and in fair-poor perceived health status (48%). Signiﬁ-
cantly, those not using any antihypertensive medications for BP
control were younger, from white racial backgrounds (82% vs.
77%, P ¼ 0.033), fewer of black race (12% vs. 18%, P ¼ 0.038), single
(51% vs. 43%, P ¼ 0.048), with 11% fewer covered by private
insurance (47% vs. 58%), 7% more uninsured (13% vs. 6%), and 4%
more covered by public insurance (40% vs. 36%) than antihyper-
tensive medication users. No signiﬁcant differences existed
between the groups for region, sex, educational attainment,
poverty status, perceived health status, body mass index, or
comorbidity level.Table 2 presents unadjusted health services utilization and
medication use results. Among the nonhypertensive medication
user group, we saw signiﬁcantly greater mean nights hospitalized
(3.6 nights vs. 1.7 nights, P ¼ 0.012) and signiﬁcantly lower
disease-speciﬁc (diabetes- and hypertension-related) ofﬁce visits
and drug ﬁlls than among those using antihypertensive pharma-
cotherapy. The number of all-cause hospitalization events per
1000 patient months was 17% signiﬁcantly greater for the no
antihypertensive pharmacotherapy group (41.0 vs. 23.5, P ¼
0.007). Signiﬁcantly, in this cohort, diabetes pharmacotherapy
showed that approximately 13% used no antidiabetic medica-
tions for diabetes management. In the no antihypertensive
pharmacotherapy group, 13.4% more used no diabetes-
controlling medication (24.5 vs. 11.1, P o 0.001) and 8.3% more
used insulin only (16.5 vs. 8.2, P o 0.001) compared with
antihypertensive medication users.
Table 3 presents adjusted results. Although all-cause ED visit
utilization was a nonsigniﬁcant ﬁnding after adjustment, the
odds of all-cause ED visits in the non-antihypertensive medica-
tion group were 1.24 times the odds of all-cause ED visits in the
antihypertensive medication group. ED visits for hypertension-
related diagnosis were lower among those not using any
hypertension-controlling pharmacotherapy. Signiﬁcantly, for this
cohort with diabetes and coexistent hypertension, the odds of
Table 1 – Baseline characteristics in an adult cohort with diabetes and concomitant HTN by antihypertensive
medication use or not from MEPS pooled years 2006 to 2009
Variable All (weighted
N ¼ 38,697,003)
HTN medication use
(weighted n ¼ 32,697,480)
No HTN medication use
(weighted n ¼ 5,999,523)
P
Age (y), mean (95% CI) 62.9 (62.2–63.7) 63.2 (62.5–64.0) 61.4 (59.4–63.5) 0.089
Family total income ($),
mean (95% CI)
50,820 (48,260–53,378) 51,341 (48,589–54,092) 47,983 (41,998–53,968) 0.307
Age category (y), % 0.001
18–45 9.0 7.9 15.1
46–64 45.8 46.3 43.6
65þ 45.2 45.9 41.3
Region, % 0.687
Northeast 18.2 18.4 17.4
Midwest 19.7 20.2 17.2
South 41.8 41.6 42.5
West 20.3 19.8 22.8
Sex, % 0.445
Male 47.9 47.5 50.2
Female 52.1 52.4 49.7
Race, % 0.033
White 77.3 76.6 81.6
Black 16.6 17.5 11.5
Other 6.1 6.0 6.9
Married, % 0.048
Yes 55.9 57.1 49.5
No 44.1 42.9 50.5
Highest degree, % 0.665
High school 49.7 49.8 48.9
College 16.4 16.9 14.0
No degree 25.7 25.3 27.6
Unknown/other 8.2 7.9 9.3
Poverty line, % 0.081
Poor 21.3 20.7 24.4
Low income 16.2 15.4 20.8
Middle income 30.4 31.0 27.4
High income 32.1 33.0 27.4
Perceived health status,
%
0.066
Excellent/very good 18.8 19.2 16.3
Good 33.5 34.4 28.3
Fair/poor 47.5 46.2 54.4
Missing/unknown 0.24 0.1 1.0
Insurance coverage, % o0.001
Private 56.5 58.3 46.6
Public 36.6 35.9 40.3
Uninsured 7.0 5.8 13.1
BMI, % 0.416
Underweight/normal 15.1 14.6 18.1
Overweight 28.2 28.2 27.7
Obese 56.7 57.2 54.1
CCI score, % 0.507
0 59.5 59.1 61.6
1 5.8 5.6 7.1
2þ 34.7 32.3 31.3
Panel, % 0.928
11 30.2 30.3 29.2
12 33.5 33.3 34.4
13 36.3 36.3 36.4
BMI, body mass index; CCI, Charlson comorbidity index; CI, conﬁdence interval; HTN, hypertension; MEPS, Medical Expenditure Panel Survey;
n, weighted sample size.
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only were 0.55, and among those using both OAD medications
and insulin 0.58 times the odds of all-cause ED visits amongindividuals on insulin only while controlling for clinical and
demographic characteristics. Signiﬁcantly, the odds of all-cause
ED visits were 0.66 of those reporting excellent to very good
Table 2 – Health services utilization and medication use in an adult cohort with diabetes and concomitant HTN
by antihypertensive medication use or not from MEPS pooled years 2006 to 2009
All HTN medication use No HTN medication use P
Utilization,* mean (95% CI)
All-cause ofﬁce visits 11.9 (11.2–12.7) 12.2 (11.4–13.0) 10.5 (8.3–12.6) 0.141
All-cause outpatient visits 1.3 (1.05–1.59) 1.4 (1.02–1.68) 1.2 (0.76–1.58) 0.562
Any prescribed medication ﬁll 49.5 (47.5–51.5) 51.4 (49.5–53.3) 39.0 (32.2–45.8) o0.001
Nights in hospital 2.0 (1.65–2.32) 1.7 (1.45–1.97) 3.6 (2.12–4.99) 0.012
Diabetes-related outpatient visits 0.18 (0.14–0.22) 0.2 (0.15–0.24) 0.1 (0.05–0.16) 0.013
Diabetes-related ofﬁce visits 3.2 (2.95–3.38) 3.3 (3.1–3.6) 2.4 (1.9–2.9) 0.006
Diabetes-related prescription drug ﬁlls 12.9 (12.2–13.5) 13.4 (12.7–14) 10.3 (8.9–11.8) o0.001
HTN-related outpatient visits 0.06 (0.04–0.07) 0.06 (0.04–0.08) 0.04 (0.01–0.06) 0.120
HTN-related ofﬁce visits 1.75 (1.6–1.9) 1.9 (1.77–2.1) 0.8 (0.52–1.01) o0.001
HTN-related prescription drug ﬁlls 9.6 (9.1–10.1) 11.2 (10.7–11.7) 1.1 (0.77–1.35) o0.001
Utilization,† per 1000 patient months, mean (95% CI)
All-cause ED 30.9 (28.1–33.6) 30.2 (27.3–33.1) 34.5 (26.4–42.6) 0.338
All-cause hospitalization 26.2 (23.3–29.2) 23.5 (21.1–25.9) 41.0 (28.6–53.4) 0.007
Diabetes-related ED 2.4 (1.8–3.0) 2.2 (1.5–2.9) 3.2 (1.3–5.2) 0.349
Diabetes-related hospitalization 2.2 (1.5–2.9) 2.1 (1.4–2.9) 2.4 (0.6–4.2) 0.798
HTN-related ED 1.8 (1.2–2.4) 1.9 (1.2–2.5) 1.4 (0.2–2.6) 0.496
HTN-related hospitalization 1.4 (0.9–1.8) 1.4 (0.9–2.0) 0.9 (0–1.8) 0.318
Antidiabetic medication use, % (SE) o0.001
Yes 86.8 (0.9) 88.9 (1.0) 75.4 (2.7)
No 13.2 (0.9) 11.1 (1.0) 24.5 (2.7)
Insulin only o0.001
Yes 9.5 (0.8) 8.2 (0.7) 16.5 (2.7)
No 90.5 (0.8) 91.8 (0.7) 83.4 (2.7)
OAD medication only o0.001
Yes 60.5 (1.2) 62.6 (1.4) 49.0 (3.5)
No 39.5 (1.2) 37.4 (1.4) 51.0 (3.5)
Insulin and OAD medication both 0.002
Yes 16.8 (1.1) 18.1 (1.2) 9.9 (2.0)
No 83.2 (1.1) 81.9 (1.2) 90.1 (2.0)
Antihypertensive drug use, % (SE)
Yes 84.5 (1.0) 100
No 15.5 (1.0) 100
Diuretic 24.5 (1.2) 29.0 (1.3)
ACE inhibitors 41.9 (1.2) 49.6 (1.4)
Angiotensin 16.2 (0.9) 19.2 (1.1)
Beta blocker 29.8 (1.1) 35.3 (1.3)
Calcium channel 18.5 (1.1) 21.9 (1.2)
Antiadrenergic 6.2 (0.6) 7.4 (0.7)
ACE, angiotensin-converting enzyme; CI, conﬁdence interval; ED, emergency department; HTN, hypertension; MEPS, Medical Expenditure
Panel Survey; OAD, oral antidiabetic; SE, standard error.
* Average total number of visits for health services per year.
† Total number of events per 1000 patient months during 2-y period.
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their health status less optimally. In addition, the odds of all-
cause ED visits were signiﬁcantly greater by 1.39 for single
persons than for married persons and 1.40 for those covered by
public insurance than for those privately insured. Individuals
with a CCI score of 2 or more showed an 81% increase in the odds
of all-cause ED utilization than did those with no comorbidity
(CCI score ¼ 0).
All-cause hospitalization showed a signiﬁcant association
with antihypertension medication users versus nonusers after
adjustment. Among this adult cohort with diabetes and concom-
itant hypertension, the odds of all-cause hospitalization in no
antihypertensive pharmacotherapy group users were 1.64 times
the odds of all-cause hospitalization in those using antihyper-
tension medications. The odds of all-cause hospitalization in
individuals using OAD medications only were 0.52 times the
odds of all-cause hospitalization in those not using antidiabeticmedications. Compared with those with no additional comorbid-
ities (CCI score ¼ 0), the odds of all-cause hospitalization for
those with a CCI score of 1 were 3.45 and for those with a CCI
score of 2 or more were 2.14. No signiﬁcant differences existed
between the two groups for the odds of hospitalization by
insurance status. Those with fair-poor perceived health status
were signiﬁcantly more likely to be hospitalized than were those
with excellent-very good health status. No associations were
found between antihypertensive medication use and
hypertension-related medical utilization.
Figure 2 illustrates the comparisons between antihyperten-
sion medication users and nonusers to the overall sample for
annualized average total and disease-related expenses including
medical and drug expenses. Signiﬁcant differences existed
between antihypertension medication users and nonusers for
annualized average total diabetes-related expenses (Fig. 2B), as
well as for hypertension-related expenses (Fig. 2C).
Table 3 – Association between the likelihood of ED visits or hospitalizations and HTN medication use in an
adult cohort with diabetes and concomitant HTN from MEPS pooled years 2006 to 2009
Independent variable ED visit: OR (95% CI) Hospitalization: OR (95% CI)
All cause HTN-related All cause HTN-related
HTN medication use
Yes 1.00 1.00 1.00 1.00
No 1.24 (0.98–1.69) 0.51 (0.20–1.30) 1.64 (1.22–2.20)* 0.51 (0.14–1.82)
Diabetes medication use
Insulin only 1.00 1.00 1.00 1.00
OAD medication only 0.55 (0.33–0.89)† 0.85 (0.29–2.51) 0.52 (0.35–0.77)‡ 0.61 (0.16–2.27)
Insulin þ OAD medication 0.58 (0.39–0.87)† 1.03 (0.40–2.61) 0.70 (0.43–1.13) 0.92 (0.36–2.34)
None 0.66 (0.43–1.01) 0.74 (0.26–2.10) 0.54 (0.31–0.92)* 0.53 (0.17–1.67)
Age (y)
18–45 1.00 1.00 1.00 1.00
46–64 0.88 (0.60–1.30) 1.58 (0.62–4.05) 1.46 (0.94–2.27) 1.54 (0.33–7.08)
65þ 0.87 (0.58–1.30) 1.30 (0.48–3.56) 1.82 (1.18–2.81)† 1.02 (0.24–4.68)
Sex
Female 1.00 1.00 1.00 1.00
Male 0.83 (0.66–1.06) 0.51 (0.26–1.03) 0.88 (0.69–1.12) 1.06 (0.52–2.15)
Race
White 1.00 1.00 1.00 1.00
Black 0.95 (0.74–1.21) 1.26 (0.66–2.37) 1.10 (0.84–1.45) 1.74 (0.88–3.43)
Other 0.69 (0.46–1.02) 1.62 (0.61–4.30) 0.61 (0.37–1.02) 1.79 (0.64–5.00)
Married
Yes 1.00 1.00 1.00 1.00
No 1.39 (1.10–1.77)† 1.90 (1.06–3.40)* 1.20 (0.94–1.53) 1.50 (0.77–2.90)
Perceived health status
Excellent-very good 1.00 1.00 1.00 1.00
Good 0.88 (0.64–1.20) 0.34 (0.14–0.84)† 0.99 (0.69–1.42) 0.62 (0.22–1.73)
Fair-poor 1.26 (0.94–1.68) 0.65 (0.33–1.30) 1.55 (1.12–2.15)‡ 0.85 (0.36–2.02)
Insurance
Private 1.00 1.00 1.00 1.00
Public 1.40 (1.05–1.87)* 2.37 (1.17–4.81)† 1.14 (0.97–1.49) 2.67 (1.09–6.50)*
Uninsured 1.23 (0.81–1.88) 2.70 (0.77–9.45) 0.89 (0.55–1.46) 1.33 (0.31–5.79)
Poverty category
High 1.00 1.00 1.00 1.00
Middle 0.94 (0.68–1.30) 0.72 (0.30–1.72) 1.01 (0.79–1.54) 1.11 (0.41–3.01)
Low 0.93 (0.63–1.37) 0.43 (0.19–1.02) 1.48 (1.02–2.15)* 0.77 (0.23–2.58)
Poor 1.10 (0.76–1.60) 1.01 (0.45–2.27) 1.33 (0.94–1.87) 1.48 (0.60–3.62)
Charlson comorbidity index score
0 1.00 1.00 1.00 1.00
1 1.81 (1.08–3.05)* 0.38 (0.11–1.36) 3.45 (2.04–5.82)‡ 0.13 (0.02–0.99)*
2þ 1.82 (1.44–2.29)‡ 1.54 (0.81–2.95) 2.14 (1.68–2.73)‡ 1.65 (0.84–3.27)
CI, conﬁdence interval; ED, emergency department; HTN, hypertension; MEPS, Medical Expenditure Panel Survey; OAD, oral antidiabetic; OR,
odds ratio.
* P o 0.05.
† P o 0.01.
‡ P o 0.001.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 1 – 6 156Table 4 presents the associations between antihypertensive
medication use and total expenses or medical utilization–related
expenses. Compared with individuals using antihypertensive
medication(s), the group not using any antihypertension phar-
macotherapy showed 29% (log coefﬁcient ¼ 0.34) lower annual-
ized average total expenses as well as 27% (log coefﬁcient ¼
0.32) lower annualized average medical utilization costs after
translating log-transformed coefﬁcients. Total expenses were
43% (log coefﬁcient ¼ 0.57) lower for those using OAD medi-
cations only, or 56% (log coefﬁcient ¼ 0.82) lower for those not
using antidiabetic medications than for those using only insulin.
Individuals with fair-poor perceived health status incurred 58%
(log coefﬁcient ¼ 0.46) higher total and annualized averageutilization-related costs than did those with excellent-very good
perceived health status, respectively. As comorbidity scores
increased, we saw a corresponding increase in total expenses
(88%–99%), as well as in annualized average medical utilization–
related expenses (105%–161%). Table 5
Our subgroup analysis showed a greater likelihood for ED
utilization and hospitalization among those not using any
hypertension-controlling medications who reported fair-poor
health status and had a CCI score of more than 2. The subpopu-
lation analysis also showed no signiﬁcant differences between
hypertension medication users and nonusers among those with
excellent-very good and good perceived health status or those
with CCI scores of less than 2 (Table 2).
02000
4000
6000
8000
10000
12000
14000
All HTN
medicaon use medicaon use
No HTN
H
ea
lt
h 
ca
re
 e
xp
en
se
s 
(U
S 
$)
Drug expense
Medical expense
0
500
1000
1500
2000
2500
All HTN medicaon
use
No HTN
medicaon use
H
ea
lt
h 
ca
re
 e
xp
en
se
s 
(U
S 
$)
Drug expense
Medical expense
0
200
400
600
800
1000
1200
All HTN medicaon
use
No HTN
medicaon use
H
ea
lt
h 
ca
re
 e
xp
en
se
s 
(U
S 
$)
Drug expense
Medical expense
Fig. 2 – Comparisons of annualized average total health care
expenses (A) and diabetes-related (B) and HTN-related (C)
expenses in an adult cohort with diabetes and concomitant
HTN by antihypertensive medications or not from MEPS
pooled years 2006 to 2009. Notes: Annualized average total
expenses ¼ drug expense þ medical expense; t tests were
used to compare total and disease-related expenses between
HTNmedication users and those with no anti-HTNmedication
use. (A) Annualized average total expenses, P ¼ 0.412; (B)
Annualized average diabetes-related expenses, P ¼ 0.013; (C)
Annualized average HTN-related expenses, P o 0.001. HTN,
hypertension; MEPS, Medical Expenditure Panel Survey.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 1 – 6 1 57Discussion
Our population-level prevalence for hypertension among adults
with diabetes was similar to previous research [16]. Thepercentage of those not using antihypertension medication(s)
was slightly better than that reported in a nine-state Medicaid
population [40], but overall was suboptimal. The signiﬁcantly
greater average number of nights in the hospital, greater percen-
tages for all-cause ED and all-cause hospitalization, as well as
odds for hospitalization among the no antihypertensive pharma-
cotherapy group than among antihypertensive medication users
among adults with diabetes and concomitant hypertension
suggest areas to investigate further in regard to potential poor
disease management or health outcomes. Future research could
try to disentangle differences between short-term and long-term
costs and health services utilization among those with diabetes
and concomitant hypertension. By using antidiabetic medication
usage to substitute for fully speciﬁed diabetes diagnoses not
provided in MEPS public use data, we saw signiﬁcantly fewer ED
visits and hospitalizations among OAD medication users than
among those prescribed insulin only. Hypertension in type 1
diabetes often stems from nephropathy, whereas essential
hypertension is central in type 2 diabetes [41]. Although we did
not assess associated renal disease, future research could exam-
ine renal status in individuals with diabetes and concomitant
hypertension among no antihypertensive pharmacotherapy
group users compared with the overall adult population with
diabetes, as well as among those with concomitant hypertension
prescribed antihypertensive medications.
We observed lower odds for medical events among insulin
and an OAD medication users than among those prescribed
insulin only. Factors associated with type 1 versus type 2 diabetes
may have affected these ﬁndings. Point in time level of glucose
control or consistency of glucose control may affect medical
utilization. The lack of laboratory and physical ﬁndings in MEPS
limited our study. Future research could use fully speciﬁed ICD-9-
CM codes provided in MEPS conﬁdential ﬁles to distinguish
between type 1 and type 2 diabetes or collect laboratory results
and physical ﬁndings to assess utilization and cost information
between antihypertension medication users and nonusers and
further examine the information over various time frames.
Although 87% in the no antihypertensive pharmacotherapy
group were insured, 13% were uninsured. Given tight BP control
guidelines for individuals with diabetes and comorbid hyper-
tension, one would expect uninsured individuals to show sig-
niﬁcantly greater ED visits or hospitalizations. Our signiﬁcant
utilization differences by insurance coverage were limited to
those covered by public insurance. Our small uninsured sample
size limits these ﬁndings. Issues not assessed in our study such
as fragmented care or personal disengagement from health
services may explain some utilization differences between public
and private insurance [42]. We were unable to examine the
timeliness of periodic ambulatory visits for disease management.
Annualized average total expenses and medical expenses
were lower for those without BP-controlling medications in the
presence of comorbid essential hypertension. These ﬁndings
differed from previous research reporting a net economic return
for increased drug utilization and adherence to treatment guide-
lines in chronic conditions including diabetes and hypertension
[43], as well as increased costs for those with poor BP control [44].
A systematic review assessing cost-effective interventions to
prevent and control diabetes, its complications, and comorbid-
ities found 4 of 56 studies meeting their inclusion criteria
reporting cost-effectiveness results for intensive hypertension
control [45]. Of these, two were conducted in the United Kingdom
and two in the United States. All four studies used a lifetime time
horizon and reported strong evidence to support costs savings for
intensive hypertension control [46–49]. Our results differed from
these studies. Our time horizon was much shorter, over 2 years,
versus a long-term lifetime time horizon. Short-term cost savings
from not taking BP-controlling medication in the presence of
Table 4 – Association between average annualized total expenses (medication þmedical utilization) or medical
utilization expenses and HTN medication use in a cohort of adults with diabetes and concomitant HTN from
MEPS pooled years 2006 to 2009
Independent variable Average annualized total expenses: Log
coefﬁcient (SE), % change
Average annualized medical utilization
expenses: Log coefﬁcient (SE), % change
All cause HTN-related All cause HTN-related
HTN medication use
Yes 0 0 0 0
No 0.34 (0.11)* 3.82 (0.01)† 0.32 (0.13)* 2.25 (0.01)†
28.8% 96.2% 27.4% 89.5%
Diabetes medication use
Insulin only 0 0 0 0
OAD medication only 0.57 (0.09)† 0.07 (0.00)† 0.37 (0.18)† 0.46 (0.00)†
43.4% 7.3% 30.9% 58.4%
Insulin þ OAD medication 0.09 (0.09) 0.09 (0.00)† 0.01 (0.20) 0.44 (0.00)†
8.6% 9.4% 1.01% 55.2%
None 0.82 (0.13)† 0.26 (0.00)† 0.37 (0.25)† 0.13 (0.00)†
56.0% 22.9% 30.9% 13.9%
Age (y)
18–45 0 0 0 0
46–64 0.13 (0.00)† 0.48 (0.00)† 0.36 (0.00)† 0.17 (0.00)†
13.9% 61.6% 43.3% 18.5%
65þ 0.22 (0.00)† 0.51 (0.01)† 0.41 (0.00)† 0.25 (0.00)†
24.6% 66.5% 50.7% 28.4%
Sex
Female 0 0 0 0
Male 0.12 (0.06)‡ 0.11 (0.01)† 0.12 (0.02)‡ 0.07 (0.00)†
11.3% 10.4% 11.3% 6.8%
Race
White 0 0 0 0
Black 0.15 (0.07)* 0.25 (0.01)† 0.21 (0.10)* 0.10 (0.00)†
13.9% 28.4% 18.9% 10.5%
Other 0.43 (0.17)† 0.14 (0.02)† 0.58 (0.20)† 0.34 (0.02)†
34.9% 15.0% 44.0% 40.5%
Married
Yes 0 0 0 0
No 0.01 (0.00) 0.18 (0.01)† 0.03 (0.01) 0.23 (0.00)†
1.0% 19.7% 3.0% 25.9%
Perceived health status
Excellent-very good 0 0 0 0
Good 0.11 (0.07)† 0.15 (0.00)† 0.09 (0.00)† 0.17(0.01)†
11.6% 16.2% 9.4% 18.5%
Fair-poor 0.46 (0.07)† 0.39 (0.00)† 0.55 (0.01)† 0.56 (0.01)†
58.4% 47.7% 73.3% 75.1%
Insurance
Private 0 0 0 0
Public 0.11 (0.07) 0.14 (0.00)† 0.25 (0.12)‡ 0.31 (0.00)†
10.4% 15.0% 22.1% 36.3%
Uninsured 0.98 (0.15)† 0.31 (0.00)† 1.60 (0.25)† 0.46 (0.00)†
62.5% 26.7% 79.8% 63.1%
Poverty category
High 0 0 0 0
Middle 0.07 (0.00)* 0.09 (0.01)† 0.11 (0.00)† 0.02 (0.00)*
7.3% 8.6% 10.4 2.0%
Low 0.03 (0.00) 0.07 (0.00)† 0.05 (0.00)* 0.06 (0.00)†
3.0% 6.8% 5.1% 6.2%
Poor 0.02 (0.00) 0.11 (0.00)† 0.13 (0.00)† 0.34 (0.00)†
2.0% 11.6% 13.9% 40.5%
Charlson comorbidity index score
0 0 0 0 0
1 0.63 (0.14)† 0.42 (0.00)† 0.72 (0.21)† 0.75 (0.01)†
87.8% 52.2% 105.4% 111.7%
2þ 0.69 (0.06)† 0.25 (0.00)† 0.96 (0.09)† 0.53 (0.00)†
99.3% 28.4% 161.2% 69.9%
HTN, hypertension; MEPS, Medical Expenditure Panel Survey; OAD, oral antidiabetic; SE, standard error.
* P o 0.01.
† P o 0.001.
‡ P o 0.05.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 1 – 6 158
Table 5 – Subpopulation analysis for perceived health status and comorbidity by health services utilization (ED
and hospitalization) in a cohort of anti-HTN medication users versus nonusers in adults with diabetes and
concomitant HTN from MEPS pooled years 2006 to 2009
Variable HTN medication use (yes/no) ED visit Hospitalization
% (SE) P % (SE) P
Perceived health status
Excellent-very good Yes 35.3 (3.1) 0.412 25.3 (2.8) 0.481
No 28.5 (7.3) 31.1 (8.2)
Good Yes 31.8 (2.3) 0.397 33.6 (7.2) 0.251
No 37.8 (7.2) 25.7 (2.2)
Fair-poor Yes 44.9 (2.0) 0.042 39.7 (2.1) 0.005
No 54.6 (4.3) 52.3 (4.0)
Charlson comorbidity index score
0 Yes 32.0 (1.7) 0.271 23.8 (1.5) 0.431
No 36.9 (4.1) 27.0 (3.6)
1 Yes 48.3 (6.5) 0.538 50.6 (5.1) 0.042
No 58.2 (14.9) 72.5 (10.1)
2þ Yes 48.0 (2.5) 0.036 42.9 (2.6) 0.001
No 61.0 (5.4) 69.0 (4.7)
HTN, hypertension; ED, emergency department; MEPS, Medical Expenditure Panel Survey; SE, standard error.
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Our results may have stemmed from short-term medication cost
saving, or possible overall disengagement from regular, custom-
ary care, which drove down short-term costs but did not reﬂect
the long-term economic burden of forgone care. Individuals with
diabetes may be willing to cut short-term costs without fully
understanding long-term consequences. The 64% signiﬁcantly
greater hospitalization among those without hypertension-
controlling medication(s) may not bode well for minimizing
long-term costs particularly if the increased likelihood for hospi-
talization can be linked to complications stemming from inad-
equate BP control such as increased risk for end-stage renal
disease or cardiovascular complications. Because MEPS surveys
individuals only over 2 years, we caution against suggesting that
our lower cost ﬁndings would hold over the long-term. The short-
term time horizon of the MEPS database presents a limitation for
this research. Discovering a difference between long-term and
sort-term cost drivers in individuals with diabetes and coexistent
hypertension warrants further research.
Although nonsigniﬁcant, all-cause presentations were more
frequent than hypertension for ED visits. This may reﬂect a
similar pattern as national trends for the leading causes of ED
visits or chronic disease presentations for ED visits [50] or may be
associated with underdiagnoses or underreporting for hyper-
tension [51].
BP measures were not collected by MEPS, thus preventing us
from determining the level of BP control between antihyperten-
sive medication users and nonusers. Our study did not assess
medication adherence for those already prescribed antihyperten-
sion pharmacotherapy. We examined individuals with coexistent
hypertension who showed no antihypertensive medication use in
the presence of known diagnosed essential hypertension. We
were not able to examine whether the BP level warranted
pharmacotherapy intervention. Future research could examine
relationships between BP-controlling medication use and none
and hypertension-related health expenditures.
As expected, those with higher comorbidity and lower per-
ceived health status showed signiﬁcantly greater total and
annualized average costs. Comorbidity burden and low perceived
health status may serve as signiﬁcant inﬂuencing factors driving
costs in those with diabetes and concomitant hypertension.
Future research could further examine how interventions tominimize the comorbidity burden or enhance health status serve
to lower costs [42].
Our data precluded assessing disease severity, actual BP levels,
or differences in BP control between groups. Our results showed
nonsigniﬁcant differences in baseline characteristics for region,
sex, level of education, socioeconomic status, perceived health
status, body mass index, or CCI. Subsequent subpopulation anal-
ysis, not reported here, also showed nonsigniﬁcant differences
between hypertensive medication users and nonusers for the
above-mentioned covariates except classiﬁcations for lower per-
ceived health status and CCI score of 2 or more. To address disease
severity, future research could link the MEPS drug use, cost, and
utilization information to the National Health Interview Survey to
assess the level of BP control [52]. Our results suggest those in the
no antihypertensive pharmacotherapy group with poor perceived
health status or higher comorbidity as a vulnerable group warrant-
ing further research. We could not assess the reasons why those
with diabetes and coexisting hypertension reporting poor perceived
health and higher comorbidity burden reported no pharmacother-
apy intervention for BP control. Future research could compare
long-term versus short-term health care costs in these individuals.
Like any retrospective observational study, our research has
several limitations. First, causal inferences may not be drawn.
The 64% signiﬁcantly greater likelihood for hospitalization among
non-antihypertensive medication users, however, suggests that
the lack of antihypertension pharmacotherapy intervention in
individuals with diabetes and comorbid essential hypertension
contributes to increased hospitalizations. We could not control
for medication compliance or determine whether individuals
received but never ﬁlled antihypertensive medication prescrip-
tions, or identify those who managed their hypertension with
diet and lifestyle interventions. MEPS public use ﬁles only provide
broad diagnostic categories in three-digit ICD-9-CM codes or the
CCS-derived clinical classiﬁcation codes. This limited our ability
to assess ﬁner diagnostic gradations. We attempted to control for
different diagnostic gradations in diabetes with a variable for
type of glycemic-controlling medication. MEPS does not elicit
information about individual understanding and choice regard-
ing disease management or risks associated with having diabetes
and concomitant hypertension. Finally, MEPS does not provide
laboratory values, or physical examination ﬁndings such as BP
values, limiting the ability to control for disease severity.
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spective research designs such as selection bias, missing or
incomplete information, recall bias, or misclassiﬁcation stem-
ming from coding errors. The MEPS drug database, however,
presents accurate representations of the number of drug ﬁlls and
total drug expenditures when compared with claims data [53].
We suggest our ﬁndings derived from the MEPS drug data serve as
an accurate representation of antihypertension drug use and
associated costs in individuals with diabetes and concomitant
hypertension. MEPS validation studies show that the households
in the survey accurately report hospitalizations and underreport ED
and ofﬁce visits [54]. Our ED utilization–related estimates as well as
total medical utilization expenses and ED expenses may be low.
This study observed signiﬁcantly greater in-patient hospital-
izations and lower total and average annualized average medical
expenses among those not reporting any antihypertension phar-
macotherapy use than among those using antihypertension
medications in a cohort of adults with diabetes and coexistent
essential hypertension. Taken in light of tight BP control guide-
lines and known poor health outcomes from elevated BPs in
individuals with diabetes, this group may represent a vulnerable
population deserving additional research and health care pro-
vider attention.
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